EGFR 突变阳性非小细胞肺癌脑转移对达可替尼的显著反应
Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib.
作者信息
Kudo Kenichiro, Kawakado Keita, Kawajiri Tomoka, Nishi Tatsuya, Makimoto Go, Tamura Tomoki, Kuyama Shoichi, Tanimoto Mitsune
机构信息
Department of Respiratory Medicine, Iwakuni Clinical Center, Japan.
出版信息
Intern Med. 2020 Jul 15;59(14):1739-1740. doi: 10.2169/internalmedicine.4449-20. Epub 2020 Apr 16.
The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutation-positive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases.
达可替尼是治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）的关键药物，其对中枢神经系统的疗效尚不清楚。我们在此介绍使用达可替尼治疗一名老年患者EGFR突变阳性NSCLC的多发脑转移瘤的经验。本病例报告表明，达可替尼可能是脑转移患者的重要治疗选择。
Zotero 插件